"It is very exciting to be a contributor to cross-functional, multifaceted teams with the same goal in mind – to bring the best anti-cancer medicines to patients that need them the most."
I joined the Oncology Biomarker Development group at Genentech in 2011, following my postdoctoral research at Massachusetts General Hospital / Harvard Medical School. I was attracted to Genentech as I had a passion to translate pre-clinical research into therapies for biomarker-defined patient populations.
Predictive biomarkers are critical to the vision of precision medicine. My role at Genentech is to develop and test biomarker hypotheses to enable clinical development of experimental medicines in the most appropriate patient populations.
npj Breast Cancer 2, Article number: 16022 (2016), doi:10.1038/npjbcancer.2016.22
My group focuses on two main areas: (1) to develop and implement robust biomarker strategies that enable clinical development of experimental therapeutics; and (2) to decipher the biomarker landscape of breast cancer to study biomarker prevalence and overlap, as well as to determine any prognostic implications associated with key patient subsets.